Introduction
Moderna, one of the leading drugmakers that developed a successful COVID-19 vaccine, Spikevax, is currently facing financial and strategic challenges as it transitions into a post-pandemic market. The company is working to resize its production footprint to align with the current needs.
Financial Performance:
- In the fourth quarter of 2024, Moderna’s cost of sales reached $739 million. This includes $193 million in inventory write-downs and $259 million in production wind-down costs.
- A significant $238 million charge was attributed to the cancellation of a contract manufacturing agreement during the quarter.
- Moderna’s CFO, Jamey Mock, mentioned $500 million in inventory write-downs and about $100 million of unutilized manufacturing capacity in 2024.
- Fourth-quarter sales in 2024 were $1 billion, a significant decrease from the $2.8 billion generated in the same period in 2023.
- Spikevax contributed $923 million, while the new RSV shot mRESVIA generated only $15 million during the same period.
- For the entire year 2024, Moderna’s revenue was $3.2 billion, which is approximately a 72% decrease from the $6.8 billion in revenue from the previous year.
- Moderna anticipates generating revenue between $1.5 billion and $2.5 billion in 2025, with the majority expected in the latter half of the year due to the seasonal nature of the vaccine market.
Challenges:
- Accurately gauging vaccine demand in the current endemic market with both Spikevax and mRESVIA.
- The company is navigating the seasonal ebb and flow of immunizations in highly competitive fields.
- Moderna is undergoing resizing of its production footprint to meet post-pandemic needs, incurring costs.
